The impact of pomalidomide-containing induction on stem cell mobilization and engraftment in multiple myeloma: a single-center experience
Annals of Hematology · 10.08.2026 · 105 (12)
DOI: 10.1007/s00277-026-07205-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Hematology, online erschienen am 10.08.2026. Verfasst von Lifen Kuang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The First Affiliated Hospital of Sun Yat-sen University, No. 58, Zhongshan Er Road, Guangzhou, Guangdong, 510080, China. Hauptthemen laut MEDLINE: Multiple Myeloma, Hematopoietic Stem Cell Mobilization, Thalidomide. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China.
Themen: Mobilisation
Abstract (Originalsprache)
BACKGROUND: Autologous stem cell transplantation (ASCT) is the standard intensification therapy for eligible newly diagnosed multiple myeloma (NDMM) patients. While lenalidomide impairs hematopoietic stem cell (HSC) mobilization, data regarding pomalidomide (POM)-containing induction remain extremely limited. METHODS: This single-center, retrospective cohort study analyzed NDMM patients undergoing HSC mobilization with high-dose cyclophosphamide (CTX) plus pegylated granulocyte colony-stimulating factor between 2023 and 2025. A 1:1 propensity score matching (PSM) was performed to balance baseline characteristics. RESULTS: From 111 patients initially included, 33 matched pairs (n = 66) were analyzed. The incidence of poor mobilization was similar between the POM and control groups (36.4% vs. 30.3%, P = 0.602). However, the POM group exhibited a marginally lower total CD34 + cell yield (median: 5.81 vs. 7.21 × 10⁶/kg, P = 0.059) and a significantly lower proportion of patients achieving the optimal target of ≥ 6 × 10⁶ cells/kg (45.5% vs. 72.7%, P = 0.024). Borderline increases in plerixafor (PXF) requirements (87.9% vs. 69.7%, P = 0.071) were observed with POM. Within the POM cohort, concomitant daratumumab (Dara) exposure significantly reduced total CD34 + yields (median: 5.19 vs. 8.24 × 10⁶/kg, P = 0.014) and increased PXF requirements (100.0% vs. 66.7%, P = 0.012). Post-ASCT engraftment kinetics were comparable (all P > 0.05). CONCLUSIONS: POM-containing induction reduces the likelihood of achieving optimal HSC collection targets and increases reliance on on-demand PXF, a negative impact further compounded by concomitant Dara use. Nonetheless, it does not preclude minimum dose collection or compromise long-term engraftment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, The First Affiliated Hospital of Sun Yat-sen University, No. 58, Zhongshan Er Road, Guangzhou, Guangdong, 510080, China.
- Department of Hematology, The First Affiliated Hospital of Sun Yat-sen University, No. 58, Zhongshan Er Road, Guangzhou, Guangdong, 510080, China. ljuan@mail.sysu.edu.cn.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Kuang, L., Chen, M., Li, X., Huang, B., & Li, J. (2026). The impact of pomalidomide-containing induction on stem cell mobilization and engraftment in multiple myeloma: a single-center experience. Annals of Hematology, 105(12). https://doi.org/10.1007/s00277-026-07205-8
Vancouver
Kuang L, Chen M, Li X, Huang B, Li J. The impact of pomalidomide-containing induction on stem cell mobilization and engraftment in multiple myeloma: a single-center experience. Annals of Hematology. 2026;105(12). doi:10.1007/s00277-026-07205-8
BibTeX
@article{Kuang2026,
author = {Kuang, Lifen and Chen, Meilan and Li, Xiaozhe and Huang, Beihui and Li, Juan},
title = {The impact of pomalidomide-containing induction on stem cell mobilization and engraftment in multiple myeloma: a single-center experience},
journal = {Annals of Hematology},
year = {2026},
volume = {105},
number = {12},
doi = {10.1007/s00277-026-07205-8}
}
EUVIMED